San

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting

Presentation Details Statistically Significant Clinical Results forSB-509 in Development for Treatment of Diabetic Neuropathy CHICAGO, June 22, 2007 /PRNewswire-FirstCall/ -- SangamoBioSciences, Inc. announced today the presentation of encouragingPhase 1 clinical data from its ZFP Therapeutic(TM) program at the67th Scientific Sessions of the American Diabetes Association(ADA). As disclose...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

First RNA Antagonist Medicine to Be Tested in Patients ReducesSeverity of Adult Leukaemia Copenhagen, 6th June 2007 - Santaris Pharma, the Danishbiopharmaceutical company, announced today that SPC2996, theCompany's new RNA Antagonist of Bcl-2, has shown early evidence ofefficacy in an initial Phase I/II clinical study in ChronicLymphocytic Leukaemia (CLL). The results of the study...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alvespimycin, its second-generation Hsp90inhibitor, demonstrated promising antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that KOS-1584/R1645, an epothilone underco-development with Roche, demonstrated promising antitumoractivity and tolerability in patients with solid tumors.KOS-1584/R1645 showed activity in 32% of patients (13 of 41evaluable) including activity in pati...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor, tanespimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of antitumor activity and tolerability in patients withmult...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that tanespimycin demonstrated antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...

Antidepressant Use May Boost Fracture Risk, From Harvard Women's Health Watch

BOSTON, May 29, 2007 /PRNewswire-USNewswire/ -- Evidence isaccumulating that depression is a risk factor for osteoporosis,reports the June 2007 issue of Harvard Women's Health Watch. Arecent study found that people ages 50 and over who regularly tookantidepressants called selective serotonin reuptake inhibitors(SSRIs) had double the rate of fractures as people not using suchmedications....

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

New data on Eloxatin(R), Taxotere(R) and on three investigationalagents (VEGF Trap, S-1 and TroVax(R)) will be presented at the 43rdannual ASCO meeting BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced today that a total of 375 abstractsindicative of its oncology commitment have been accepted for the43rd Annual Meeting of the American Society of Clinical On...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interactionwith paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration ofpaliperidone extended-release (ER) tablets, blood levels of thedrug were not affected when given with a common antidepressant,according to new data presented today at the 160th Annual Meetingof the American Psychiatric Association. Paroxetine,...

ACC Sanctions Leon

WASHINGTON, May 22, 2007---The American College of Cardiology'sBoard of Trustees has approved sanctions against Martin B. Leon,M.D., F.A.C.C., arising from his statements that resulted in thebreach and consequent premature lifting of the embargo on theCOURAGE trial data presented at American College ofCardiology’s 56th Annual Scientific Session in March. The Board accepted the reco...

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

- Results Presented at 160th Annual Meeting of the AmericanPsychiatric Association - SAN DIEGO, May 21, 2007 /PRNewswire-FirstCall/ -- In adults withmajor depressive disorder, adding aripiprazole to antidepressanttherapy (ADT) resulted in significant improvement in the primaryendpoint, the Montgomery- Asberg Depression Rating Scale (MADRS)Total Score. In this six-week, randomized, placebo...

FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications

ROCKVILLE, Md., May 2, 2007-The U.S. Food and DrugAdministration (FDA) today proposed that makers of allantidepressant medications update the existing black box warning ontheir products' labeling to include warnings about increased risksof suicidal thinking and behavior, known as suicidality, in youngadults ages 18 to 24 during initial treatment (generally the firstone to two months).</p...

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting

Statistically Significant Improvements in Function in Spinal CordInjury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- SangamoBioSciences, Inc. announced today the presentation of preclinicaldata from its ZFP Therapeutic(TM) program in nerve regeneration atthe Fourteenth Annual Conference of the American Society for NeuralTherapy and Repair. The data...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

HAYWARD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated today presented preclinical data on itsproprietary nuclear export inhibitors (NEI) showing induction ofpotent, fast-acting and long-lasting anticancer activity with ahigh degree of tolerability in multiple human tumor xenograftcancer models. Kosan's NEIs are potent, specific inhibitors of CRM1,...

Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research

Bcl-2 Antagonist shown to be therapeutically effective in amouse model of Chronic Lymphocytic Leukaemia COPENHAGEN, 18 April 2007 - Santaris Pharma, the Danishbiopharmaceutical company developing RNAi drugs, yesterdaypresented encouraging data at the American Association for CancerResearch Annual Meeting in Los Angeles, showing that SPC2996, theCompany's RNA Antagonist of Bcl-2, is...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated today presented preclinical data onKOS-1803, a next-generation epothilone, showing a high level ofantitumor activity and a favorable pharmacokinetic and safetyprofile in a broad range of in vitro tests and in vivo cancermodels. KOS-1803 has been chemically engineered to have a favorabletissue distribu...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

Tanespimycin Shown to Have No Effect on QTc Interval HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- KosanBiosciences Incorporated today presented safety data frompreclinical and clinical studies of its lead Hsp90 inhibitor,tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoringof patients was conducted in four Phase 1 trials of tanespimycin.Cardiac monitoring analyses were cond...

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Mersana, acancer therapeutics company, announced today that results ofpreclinical studies with its lead product candidate, XMT-1001, willbe presented in two posters at the 2007 Annual Meeting of theAmerican Association of Cancer Research (AACR) taking place April14-18th in Los Angeles, CA. Full text of the abstracts can beviewed online at...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated announced data will be presented on theCompany's clinical and preclinical pipeline, including its Hsp90inhibitor, epothilone and nuclear export inhibitor programs, at the2007 Annual Meeting of the American Association for Cancer Research(AACR), being held in Los Angeles, April 14-18, 2007. Poste...

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice

BETHESDA, Md., April 1, 2007--Rapamycin, an FDA-approved drugnormally used to help prevent the body from rejecting organ andbone marrow transplants and also used to coat cardiac stents, washighly effective in preventing the development of tobacco-relatedlung tumors in mice. In a study published in the April 1, 2007issue of Clinical Cancer Research, researchers at the NationalCancer Insti...

CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant

- Tyrima Demonstrates Good Safety Profile and ExcellentPharmacokinetic Properties - RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ --CeNeRx BioPharma, Inc., a clinical stage company developing andcommercializing innovative treatments for diseases of the centralnervous system, today announced top-line results from a Phase Iclinical trial of Tyrima(TM), its lead candidate for the...

Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Vaxiion Therapeutics,Inc. today announced that its researchers, in collaboration withSan Diego State University, have discovered a 'minicell' vaccinedelivery system that has potential to protect against severaldisease-causing infections. These findings were published in an advance online edition ofthe journal, Vaccine, and the paper was published...